Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest pediatric asthma Stories

2012-06-18 22:20:29

GENEVA and ZURICH, June 19, 2012 /PRNewswire/ -- - AAAAI, ACAAI, EAACI and WAO launch the International Consensus (ICON) on Pediatric Asthma at the EAACI Congress 2012 - The goal of the Pediatric Asthma ICON is to ensure appropriate asthma management to control the disease and improve the quality of life of patients. - The Pediatric Asthma ICON is part of the iCAALL initiative, International Collaboration in Asthma, Allergy and Immunology. The International...

2010-11-10 00:00:39

The CareSource Foundation, part of CareSource, a non-profit, public-sector managed care company, recently announced a $75,000 Signature Grant to the Ohio Chapter of the American Academy of Pediatrics for a high-impact, statewide children's asthma pilot project. Dayton, OH (Vocus) November 9, 2010 The CareSource Foundation, part of CareSource, a non-profit, public-sector managed care company, recently announced a $75,000 Signature Grant to the Ohio Chapter of the American Academy of...

2010-03-01 13:59:00

ATLANTA, March 1 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced that Memorial Healthcare System (MHS) was honored as a finalist in the HIMSS (Healthcare Information and Management Systems Society) inaugural "Stories of Success! Leveraging HIT, Improving Quality & Safety" program. Memorial Healthcare System of South Florida, one of 16 applicants selected for recognition, used Hospira's...

2010-02-13 09:17:43

Hypnosis has potential therapeutic value in children with respiratory disorders for alleviating symptoms such as habit cough or unexplained sensations of difficulty breathing and for lessening a child's discomfort during medical procedures. Proper utilization of hypnosis as an adjunct to conventional treatment and its ability to use the mind-body connection to bring about physiological changes are explored in a provocative paper in Pediatric Asthma, Allergy & Immunology, a peer-reviewed...

2008-12-19 07:04:00

LONDON and MOUNTAIN VIEW, Calif., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulized formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for pediatric asthma and is currently in Phase III clinical development. UDB has the potential to be...

2008-09-22 09:00:12

MOUNTAIN VIEW, Calif., Sept. 22 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that it has completed patient enrollment in its Phase 3 clinical trial evaluating Unit Dose Budesonide (UDB), the company's proprietary nebulized version of budesonide, for the potential treatment of pediatric asthma. The purpose of the Phase 3 trial is to evaluate the safety and efficacy of UDB as a potential treatment of pediatric asthma in approximately 360 children from 12 months to...

2008-04-12 03:00:13

By Fiese, Barbara Winter, Marcia; Anbar, Ran; Howell, Kimberly; Poltrock, Scott This preliminary report links the literatures on family asthma management practices and on the characteristics of family interaction patterns thought to influence children's adjustment to a chronic physical illness. Specifically, this study of 60 families with a child with asthma examined the extent to which perceived burden of routine asthma care affected child mental health via its influence on parent-child...